Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Alison M. Kurimchak"'
Autor:
Jason S. Wasserman, Bulat Faezov, Kishan R. Patel, Alison M. Kurimchak, Seren M. Palacio, David J. Glass, Holly Fowle, Brennan C. McEwan, Qifang Xu, Ziran Zhao, Lauren Cressey, Neil Johnson, James S. Duncan, Arminja N. Kettenbach, Roland L. Dunbrack, Xavier Graña
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-20 (2024)
Abstract The Ser/Thr protein phosphatase 2 A (PP2A) regulates the dephosphorylation of many phosphoproteins. Substrate recognition are mediated by B regulatory subunits. Here, we report the identification of a substrate conserved motif [RK]-V-x-x-[VI
Externí odkaz:
https://doaj.org/article/6e9017a5c5d34b82817862a82164f6a6
Autor:
Anna M. Jermakowicz, Alison M. Kurimchak, Katherine J. Johnson, Florence Bourgain-Guglielmetti, Simon Kaeppeli, Maurizio Affer, Hari Pradhyumnan, Robert K. Suter, Winston Walters, Maria Cepero, James S. Duncan, Nagi G. Ayad
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Bromodomain and extra-terminal domain (BET) proteins are therapeutic targets in several cancers including the most common malignant adult brain tumor glioblastoma (GBM). Multiple small molecule inhibitors of BET proteins have been utilized i
Externí odkaz:
https://doaj.org/article/4f50f991d1904053be9db08dafc453a4
Autor:
Alison M. Kurimchak, Claude Shelton, Kelly E. Duncan, Katherine J. Johnson, Jennifer Brown, Shane O’Brien, Rashid Gabbasov, Lauren S. Fink, Yuesheng Li, Nicole Lounsbury, Magid Abou-Gharbia, Wayne E. Childers, Denise C. Connolly, Jonathan Chernoff, Jeffrey R. Peterson, James S. Duncan
Publikováno v:
Cell Reports, Vol 16, Iss 5, Pp 1273-1286 (2016)
Small-molecule BET bromodomain inhibitors (BETis) are actively being pursued in clinical trials for the treatment of a variety of cancers, but the mechanisms of resistance to BETis remain poorly understood. Using a mass spectrometry approach that glo
Externí odkaz:
https://doaj.org/article/e79692fa8e914be09f6af9dfa3135db9
Autor:
James S. Duncan, Jonathan Chernoff, Kelly E. Duncan, Carlos Herrera-Montávez, Claude Shelton, Alison M. Kurimchak
Mutation or deletion of Neurofibromin 1 (NF1), an inhibitor of RAS signaling, frequently occurs in epithelial ovarian cancer (EOC), supporting therapies that target downstream RAS effectors, such as the RAF–MEK–ERK pathway. However, no comprehens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b69d730f8d4dc56ff9a3b4f69902c3b8
https://doi.org/10.1158/1541-7786.c.6541134
https://doi.org/10.1158/1541-7786.c.6541134
Autor:
James S. Duncan, Jonathan Chernoff, Kelly E. Duncan, Carlos Herrera-Montávez, Claude Shelton, Alison M. Kurimchak
Supplemental Figure 1. MEK inhibition has minimal impact on cell viability in the majority of NF1-deficient cell lines. Supplemental Figure 2. MEK inhibition induces transcription of several RTKs in EOC cell lines. Supplemental Figure 3. Co-targeting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::720983fcffd7e62e94e162d9d04371f4
https://doi.org/10.1158/1541-7786.22515582.v1
https://doi.org/10.1158/1541-7786.22515582.v1
Autor:
Alison M. Kurimchak, Carlos Herrera-Montávez, Sara Montserrat-Sangrà, Daniela Araiza-Olivera, Jianping Hu, Ryan Neumann-Domer, Mathew Kuruvilla, Alfonso Bellacosa, Joseph R. Testa, Jian Jin, James S. Duncan
Publikováno v:
Sci Signal
Proteolysis-targeting chimeras (PROTACs) are a promising new class of drugs that selectively degrade cellular proteins of interest. PROTACs that target oncogene products are avidly being explored for cancer therapies, and several are currently in cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31a87105e626b73c1d9c83f7113b2b7c
https://europepmc.org/articles/PMC9552188/
https://europepmc.org/articles/PMC9552188/
Publikováno v:
Cancer Research. 83:2621-2621
Activating KRAS mutations frequently occur in several cancers including the majority of pancreatic ductal adenocarcinoma (96%), ~50% of colorectal cancers, and ~30% of lung adenocarcinoma. It has been shown that mutant K-ras preferentially signals th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89cb39f98e59c287e7099dbbb90b65d6
https://doi.org/10.1158/1538-7445.am2023-2621
https://doi.org/10.1158/1538-7445.am2023-2621